https://p505-15inhibitor.com/a....ssociation-involving
Nedaplatin (NDP) plays a crucial role within the chemotherapies of non-small cellular lung cancer tumors (NSCLC). Nevertheless, dose-limiting toxicities such myelosuppression and medication opposition restrict its clinical application. Herein, we meant to conquer these problems by developing a PEGylated liposomal formulation encapsulated NDP (NDP-LPs). The very first time, we found the incompatibility between NDP and natural phospholipids such as egg phosphatidylcholine (EPC) using the